Celltrion Vegzelma Biosimilar Captures 10.6% US Market Share After Comparability Analysis
Korean biopharmaceutical company Celltrion reports its Vegzelma biosimilar captured 10.6% of the U.S. market as of May. This follows the publication of an integrated pharmacokinetic analysis supporting the product's comparability to its reference drug.
Vegzelma Expands Market Presence
Celltrion's Vegzelma biosimilar achieved 10.6% of the U.S. market share as of May, according to pharmaceutical market research firm IQVIA and local market data. This marks the first time the product has exceeded the 10% threshold since its launch. In Japan, Vegzelma maintained its top position, holding a 64% market share as of March.
These figures demonstrate the product's increasing adoption in key global markets. Celltrion aims to accelerate further growth in global market share.
Scientific Evidence Supports Comparability
The journal BioDrugs published an integrated population pharmacokinetic analysis of Vegzelma (CT-P16), a biosimilar of Avastin (bevacizumab). This analysis provides evidence of the product's pharmacokinetic comparability with its reference drug.
The study combined data from two global phase 1 trials involving healthy subjects and one global phase 3 trial in patients with non-squamous non-small cell lung cancer. Researchers, in collaboration with a team led by Professor Chang Min-jung of Yonsei University, developed an integrated model using data from 834 participants and over 8,000 serum concentration measurements.
The results show Vegzelma's pharmacokinetic characteristics are comparable to U.S.- and EU-sourced reference products, with no clinically relevant differences in key parameters like clearance and central volume of distribution.
Celltrion's Strategy for Future Growth
Celltrion states this study is important because it expands clinical evidence beyond initial biosimilarity demonstrations. The company plans to continue accumulating scientific evidence through cost-efficient follow-up clinical research, rather than solely relying on data generated for regulatory approval.
This strategy aims to strengthen physician confidence in prescribing Celltrion products and support global market share expansion. A Celltrion official stated the findings objectively demonstrate Vegzelma's strength.
Amid regulatory environments streamlining biosimilar approval, Celltrion expects such integrated research models to become an important strategy for its future biosimilar portfolio.
Implications for Asia's Biopharmaceutical Sector
Celltrion's approach to post-approval clinical evidence generation offers a model for other Asian biopharmaceutical companies in the competitive global biosimilar market. As regulatory bodies adjust approval requirements, investing in comprehensive, cost-efficient follow-up studies can differentiate products and build trust among healthcare providers.
This strategy may help Asian firms not only secure market entry but also sustain growth and influence prescribing decisions in medical aesthetics and other therapeutic areas. For Asian brands and manufacturers, this demonstrates a pathway to strengthen product confidence and expand reach beyond initial regulatory hurdles.
Three newsletters, one newsroom.
The Beauty Brief delivers Asia's beauty week every Monday. Regulatory Radar tracks the rule changes that move markets. Trend Pulse decodes what consumers want next. All free to start.
